2026
August
Activated DCs go beyond priming to sustain tumoral T cell responses
August 12, 2026
A subset of cDCs within tumors expresses T cell-stimulating and immune-regulatory molecules. The exact role of these activated DCs (actDCs) in antitumor immunity remains largely unknown, and given their scarcity, they are a challenge to study. Koufaki et al. developed murine models to label and ablate CCR7+ DCs to study their role in...
Helpers don’t clock out: CD4s essential for both priming and effector phases of ICB
August 5, 2026
While CD4+ T cells are crucial for CD8+ T cell priming in ICB-induced antitumor responses, their helper role at the effector phase remains largely unknown. Ameh et al. used murine MHC-II- sarcoma models to study CD4+ T cell help during ICB treatment. Their results were recently published in Cancer Immunology Research. The researchers...
